

# Nathaniel J Rhodes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2403334/publications.pdf>

Version: 2024-02-01

90  
papers

1,583  
citations

304743

22  
h-index

377865

34  
g-index

102  
all docs

102  
docs citations

102  
times ranked

1736  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1881-1887.	5.8	129
2	Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis*. <i>Critical Care Medicine</i> , 2018, 46, 236-243.	0.9	85
3	A Review of the Clinical Pharmacokinetics of Polymyxin B. <i>Antibiotics</i> , 2019, 8, 31.	3.7	68
4	Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	65
5	Treatment Outcomes with Cefazolin versus Oxacillin for Deep-Seated Methicillin-Susceptible <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5232-5238.	3.2	63
6	Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5742-5751.	3.2	61
7	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1401-1410.	3.2	51
8	Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention. <i>Pharmacotherapy</i> , 2020, 40, 438-454.	2.6	51
9	Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	46
10	Student Characteristics Associated with Successful Matching to a PGY1 Residency Program. <i>American Journal of Pharmaceutical Education</i> , 2016, 80, 84.	2.1	43
11	Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	43
12	Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1228-1236.	3.0	43
13	24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	39
14	Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. <i>Pharmacotherapy</i> , 2018, 38, 730-738.	2.6	36
15	Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?. <i>Clinical Infectious Diseases</i> , 2020, 71, 426-432.	5.8	36
16	$\beta$ -Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 429-433.	3.0	35
17	Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia. <i>Current Infectious Disease Reports</i> , 2018, 20, 3.	3.0	34
18	Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2068-2073.	3.0	33

#	ARTICLE	IF	CITATIONS
19	An exploratory analysis of the ability of a cefepime trough concentration greater than 22Âmg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 78-83.	1.7	31
20	Diagnostic stewardship of <i>C. difficile</i> testing: a quasi-experimental antimicrobial stewardship study. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 269-275.	1.8	30
21	Impact of Loading Doses on the Time to Adequate Predicted Beta-Lactam Concentrations in Prolonged and Continuous Infusion Dosing Schemes. <i>Clinical Infectious Diseases</i> , 2014, 59, 905-907.	5.8	28
22	Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	25
23	Prevalence of a Cefazolin Inoculum Effect Associated with <i>blaZ</i> Gene Types among Methicillin-Susceptible <i>Staphylococcus aureus</i> Isolates from Four Major Medical Centers in Chicago. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	24
24	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a "Goldilocks" window. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 487-490.	2.5	21
25	Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 482-486.	2.5	21
26	Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa538.	0.9	21
27	Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 165-171.	1.8	20
28	Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 239-243.	2.5	20
29	Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed <i>Pseudomonas aeruginosa</i> Clonal Complex 446 in an Academic Medical Center. <i>Clinical Infectious Diseases</i> , 2020, 71, 1524-1531.	5.8	20
30	Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 350-355.	1.5	19
31	Unacceptably High Error Rates in Vitek 2 Testing of Cefepime Susceptibility in Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3757-3761.	3.2	17
32	Carbapenems vs. alternative $\beta$ -lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 451-458.	2.5	15
33	Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 838-844.	3.2	14
34	Engaging Pharmacy Students in Research Through Near-Peer Training. <i>American Journal of Pharmaceutical Education</i> , 2017, 81, 6340.	2.1	14
35	Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 241-246.	1.0	13
36	Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoietic Cell Transplantation. <i>Pharmacotherapy</i> , 2016, 36, 1003-1010.	2.6	13

#	ARTICLE	IF	CITATIONS
37	Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0106021.	3.2	12
38	High-Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin. <i>Clinical and Translational Science</i> , 2017, 10, 496-502.	3.1	11
39	Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible <i>Staphylococcus aureus</i> bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 225-233.	2.5	11
40	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1027-1036.	3.5	11
41	Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	10
42	Impact of body mass index on clinical outcomes in patients with gram-negative bacteria bloodstream infections. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 671-676.	1.7	9
43	Investigating the Extremes of Antibiotic Use with an Epidemiologic Framework. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3265-3269.	3.2	9
44	Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 162-169.	3.0	9
45	Impact of vancomycin treatment duration and dose on kidney injury. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 297-298.	2.5	8
46	Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 83-85.	2.2	8
47	Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. <i>Clinical Pharmacokinetics</i> , 2022, 61, 155-165.	3.5	8
48	Pharmacokinetics of centhaquin citrate in a rat model. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 56-62.	2.4	7
49	Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible <i>Staphylococcus aureus</i> bloodstream infections paired with infectious diseases consultation. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 650-654.	2.5	7
50	Factors contributing to vancomycin-resistant <i>Enterococcus</i> spp. horizontal transmission events: exploration of the role of antibacterial consumption. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 72-77.	1.8	7
51	Correlation between hospital-level antibiotic consumption and incident health care facility-onset <i>Clostridium difficile</i> infection. <i>American Journal of Infection Control</i> , 2018, 46, 270-275.	2.3	7
52	The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients. <i>Pharmacotherapy</i> , 2019, 39, 718-723.	2.6	7
53	Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105970.	2.5	7
54	Implementing Infection Prevention for Leech Therapy. <i>American Journal of Infection Control</i> , 2019, 47, S15.	2.3	6

#	ARTICLE	IF	CITATIONS
55	β-lactam dosing strategies: Think before you push. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106151.	2.5	6
56	Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
57	Eight unexpected cases of vancomycin associated acute kidney injury with contemporary dosing. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 326-332.	1.7	5
58	Perceptions and practices for beta-lactam antibiotic dosing, administration, and monitoring in critically ill patients: Current views and use among critical care and infectious diseases pharmacists. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 468-476.	1.0	5
59	Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105849.	2.5	5
60	Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational <i>In Vivo</i> Rat Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	5
61	Characterizing Risk Factors for <i>Clostridioides difficile</i> Infection among Hospitalized Patients with Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0041721.	3.2	5
62	A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime. <i>MSphere</i> , 2019, 4, .	2.9	4
63	Multidrug resistant <i>Aeromonas</i> infection following medical leech therapy: A case report and development of a joint antimicrobial stewardship and infection prevention protocol. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 349-351.	2.2	4
64	Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 568-577.	1.0	4
65	Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 742-746.	1.7	3
66	Prediction of inventory sustainability during a drug shortage. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1094-1098.	1.0	3
67	Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption Metrics. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 971-973.	1.8	3
68	Measuring the impact of varying denominator definitions on standardized antibiotic consumption rates: implications for antimicrobial stewardship programmes. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2876-2882.	3.0	3
69	Discrepancies Between Patient Self-Reported and Electronic Health Record Documentation of Medication Allergies and Adverse Reactions in the Acute Care Setting: Room for Improvement. <i>Journal of Pharmacy Technology</i> , 2019, 35, 139-145.	1.0	3
70	Quantifying the importance of active antimicrobial therapy among patients with Gram-negative bloodstream infections: Cefepime as a representative agent. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 95-97.	2.5	3
71	Effects of Advanced Pharmacy Practice Experience Characteristics on Postgraduate Year 1 Residency Match Rates. <i>Journal of Pharmacy Practice</i> , 2022, 35, 158-164.	1.0	3
72	Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2486-2488.	3.0	3

#	ARTICLE	IF	CITATIONS
73	A Simple Microsoft Excel Method to Predict Antibiotic Outbreaks and Underutilization. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 860-862.	1.8	2
74	Understanding the Components, Calculation, and Impact of Monthly and Seasonal Variation of the Standardized Antimicrobial Utilization Ratio (SAAR). <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	2
75	Impact of early antimicrobial stewardship intervention in patients with positive blood cultures: results from a randomized comparative study. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106490.	2.5	2
76	Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 199-209.	1.6	2
77	Urinary Metabolomics From a Dose-Fractionated Polymyxin B Rat Model of Acute Kidney Injury. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106593.	2.5	2
78	The Prevalence of an Inoculum Effect With Cefazolin and the Association With Certain blaZ Gene Types Among Methicillin-Susceptible <i>Staphylococcus aureus</i> Isolates From Four Major Chicago Medical Centers. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
79	Exploring the Relationship between FEV <sub>1</sub> Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies. <i>Pharmacotherapy</i> , 2020, 40, 584-591.	2.6	1
80	Re: "Limitations of classification and regression tree analysis in vancomycin exposure-response relationship studies" by Dalton et al.. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1867-1868.	6.0	1
81	Analysis of an Infectious Diseases Pharmacist on Call Pager Program to Inform Educational Efforts. <i>Journal of Pharmacy Technology</i> , 2017, 33, 146-150.	1.0	0
82	1391. Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A Systematic Review and Meta-Analysis of Observational Studies. <i>Open Forum Infectious Diseases</i> , 2018, 5, S427-S427.	0.9	0
83	1821. Understanding the Components and Calculation of the SAAR, Illustrative Data. <i>Open Forum Infectious Diseases</i> , 2018, 5, S517-S518.	0.9	0
84	1406. Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling with Bayesian Estimation in Children in the Pediatric Intensive Care Unit. <i>Open Forum Infectious Diseases</i> , 2018, 5, S433-S433.	0.9	0
85	The authors reply. <i>Critical Care Medicine</i> , 2018, 46, e725-e726.	0.9	0
86	1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime. <i>Open Forum Infectious Diseases</i> , 2018, 5, S429-S429.	0.9	0
87	Implementation of an Extended-Infusion Piperacillin-Tazobactam Dosing Protocol: Unexpected Findings when Monitoring Safety and Compliance with Smart Pump Technology. <i>Pharmacy (Basel, Switzerland)</i> , 2019, 7, 169.	1.6	0
88	Empiric Carbapenems for Nosocomial Pneumonia. <i>Chest</i> , 2021, 159, 897-899.	0.8	0
89	Writing and Thinking. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 7785.	2.1	0
90	Intermittent High-Dose Ethanol Exposure Increases Ethanol Preference in Rats. <i>Journal of Studies on Alcohol and Drugs</i> , 2015, 76, 165-173.	1.0	0